OMER News and Press, Omeros Corporation From 03/10/23

Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank. Omeros previously maintained a line of credit with Silicon Valley Bank, which the company allowed to expire in August 2022. Omer...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4...

Shares of Omeros (NASDAQ: OMER) rose by a stately 69.9% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence . Shares of the commercial-stage biopharmaceutical company jumped this week in response to a $200 mill...

Summary Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang some investors were worried about. With the additional $200M cash, now the enterprise value of the company is around $115M, which we...

Shares of Omeros Corporation (NASDAQ: OMER) skyrocketed 40.5% higher as of 11:12 a.m. ET on Monday. The huge gain came after the company announced that Rayner Surgical paid a $200 million milestone payment. This payment is related to Omeros' sale of its ophthalmology product Omidria to Ra...

Penny Stocks To Watch With News This Week One of the quickest ways to see what’s going on with specific penny stocks is to check the newsfeeds. More often than not, you’ll find an update or opinion article discussing new or potential milestones to take notice of. In this...

Omeros ( NASDAQ: OMER ) is up 35% in premarket trading after receiving a $200M milestone payment from Rayner Surgical. The payment was due to Omeros' ( OMER ) sale of ophthlamic solution Omidria (phenylephrine and ketorolac) in December  2021. Leading to the mile...

– OMIDRIA ® -Related Payment Expected to Provide Operating Capital into at Least 2025 – Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset ...

Summary Omeros corporation's hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) should be considered a free option at this point. Narsoplimab has highly compelling phase 2 data on IgAN and a compelling mechanistic rationale. Narsoplimab is one of the m...

Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...